By Susan Gonzalez
July 15, 2021
Share this with FacebookShare this with TwitterShare this with LinkedInShare this with EmailPrint this
(© stock.adobe.com)
The administration of high-dose buprenorphine therapy in hospital emergency departments (ED) may safely and rapidly diminish withdrawal symptoms and sustain craving suppression in people with opioid use disorder, improving their likelihood of accessing follow-up treatment, according to a study co-authored by Yale’s Gail D’Onofrio.
Buprenorphine is a medication approved by the U.S. Food and Drug Administration to treat opioid use disorder. Giving lower doses of the medication is the current standard of care. The study found, however, that giving higher doses of buprenorphine in EDs may provide a longer period of relief to people after they are discharged, which may help them navigate barriers to access to follow-up care before they experience withdrawal symptoms.
Emergency department-administered, high-dose buprenorphine may enhance opioid use disorder treatment outcomes
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
ED-administered high-dose buprenorphine may enhance opioid use disorder treatment outcomes
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
-derived asparaginase treatments
Company to host investor webcast in July; details to follow
DUBLIN, July 1, 2021 /PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in pediatric and adult patients one month and older who have developed hypersensitivity to
Share this article
Share this article
DUBLIN, June 30, 2021 /PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze
™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in pediatric and adult patients one month and older who have developed hypersensitivity to
E. coli-derived asparaginase.
1
Rylaze is the only recombinant erwinia asparaginase manufactured product that maintains a clinically meaningful level of asparaginase activity throughout the entire duration of treatment, and it was developed by Jazz to address the needs of patients and healthcare providers with an innovative, high-quality erwinia-derived asparaginase with reliable supply.